Balveen Singh, DO
Psychiatry · West Nyack, NYNPI 1164753745
Payments from drug & device makers
Across 884 payments — averaging $251.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$144K
- Axsome Therapeutics, Inc.$64K
- AbbVie$3K
- Alkermes, Inc.$2K
- Neurocrine Biosciences, Inc.$2K
- Neuronetics, Inc.$2K
- plus $6K from 24 others
What the payments were for
- Consulting fees$16,0007%
- Speaking & faculty fees$156,95771%
- Travel & lodging$25,72212%
- Food & beverage$23,36811%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 224 | $143,508 |
| Axsome Therapeutics, Inc. | 103 | $63,916 |
| AbbVie(2 entities) | 156 | $2,503 |
| Alkermes, Inc. | 74 | $2,342 |
| Neurocrine Biosciences, Inc. | 66 | $1,828 |
| Neuronetics, Inc. | 4 | $1,745 |
| Johnson & Johnson | 44 | $1,121 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 34 | $1,066 |
| Sunovion Pharmaceuticals Inc. | 46 | $1,041 |
| Lundbeck LLC | 29 | $681 |
| Corium, LLC | 24 | $546 |
| E.r. Squibb & Sons, L.L.C. | 19 | $339 |
| Indivior Inc. | 8 | $209 |
| Boston Scientific | 9 | $164 |
| Abbott | 2 | $162 |
| Jazz Pharmaceuticals Inc. | 9 | $147 |
| Almatica Pharma LLC | 5 | $136 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 6 | $108 |
| Vanda Pharmaceuticals Inc. | 3 | $79 |
| Novo Nordisk | 3 | $72 |
| Collegium Pharmaceutical, Inc. | 3 | $61 |
| Teva Pharmaceuticals USA, Inc. | 3 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $48 |
| Orexo US, Inc. | 2 | $44 |
| Bioxcel Therapeutics, Inc. | 1 | $25 |
| Avanir Pharmaceuticals, Inc. | 1 | $22 |
| Pfizer | 1 | $22 |
| Neos Therapeutics, LP | 1 | $21 |
| Luye Pharma (USA) Ltd. | 1 | $21 |
| Alfasigma USA, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$140,666
- Auvelity$62,382
- LYBALVI$1,896
- NEUROSTAR TMS THERAPY SYSTEM$1,633
- ARISTADA$1,423
- VRAYLAR$710
- INGREZZA$591
- ARISTADA INITIO$356
- ABILIFY MAINTENA$250
- CAPLYTA$248
- LATUDA$242
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$137
- COBENFY$125
- ABILIFY ASIMTUFII$125
- Azstarys$125
How this compares
$222,048 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abilify MaintenaAripiprazole | 42 | $119,972 |
| Invega TrinzaPaliperidone Palmitate | 11 | $103,507 |
| AustedoDeutetrabenazine | 16 | $100,783 |
| RexultiBrexpiprazole | 47 | $69,192 |
| VraylarCariprazine Hcl | 29 | $45,216 |
| Invega SustennaPaliperidone Palmitate | 11 | $37,011 |
| Risperdal ConstaRisperidone Microspheres | 20 | $22,551 |
| Chlorpromazine Hcl | 46 | $21,194 |
| Aripiprazole | 153 | $6,410 |
| Clozapine | 60 | $5,673 |
| Divalproex Sodium | 96 | $4,980 |
| Quetiapine Fumarate | 252 | $3,316 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 13 | $2,871 |
| Haloperidol | 66 | $2,724 |
| Fluphenazine Hcl | 27 | $2,717 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $143,508 | $189,16589 claims |
| Johnson & JohnsonInvega Trinza, Invega Sustenna, Risperdal Consta | $1,121 | $163,06942 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $52 | $100,78316 claims |
| AbbVieVraylar | $2,503 | $45,21629 claims |
| Almatica Pharma LLCSertraline Hcl | $136 | $976133 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in West Nyack
- Elyssa BarronWhite Plains$12.8M
- Mark DibuonoStaten Island$11.9M
- Ronald BrennerHempstead$11.5M
- Anton PorsteinssonRochester$7.6M
- Michael LiebowitzNew York$7.1M
- Leslie CitromePomona$5.7M
- John KaneGlen Oaks$4M
- Inna Yuryev-GolgerBrooklyn$3M
- Subhdeep VirkBuffalo$3M
- Paul EderNew York$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.